PR Newswire
06 Jan 2023, 17:55 GMT+10
![]() |
MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2023 /PRNewswire/ -- Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that its Board of Directors approved a ratio change of its American Depository Shares (ADSs) to Ordinary Shares (the "ADS Ratio") from the current ADS Ratio of 1 ADS representing 60 Ordinary Shares to 1 ADS representing 600 Ordinary Shares (the "ADS Ratio Change"). The ADS Ratio Change will be effective on January 9, 2023. Beginning with the opening of trading on Monday, January 9, 2023, Alterity's ADS will continue to trade on the Nasdaq Capital Market under the symbol "ATHE," but will trade on a split-adjusted basis under a new CUSIP number 02155X205.
As a result of the reverse split, every ten (10) existing ADSs will be exchanged for one (1) new ADS. The Bank of New York Mellon (the "Depositary"), as the depositary bank for the Company's ADS program, will arrange for the exchange of current ADSs for new ADSs.
No fractional new ADSs will be issued in connection with the ADS Ratio Change. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the Depositary. The ADS Ratio Change will have no impact on the Company's underlying Ordinary Shares traded on the ASX, and no Ordinary Shares will be issued or cancelled in connection with the ADS Ratio Change.
Alterity's Board of Directors approved the ADS ratio change with the objective of regaining compliance with the minimum bid price of $1.00 per share as outlined in the NASDAQ Listing Rules. The Company has until February 23, 2023 to regain compliance. The Company can give no assurance that this event will result in the company meeting NASDAQ's minimum bid price requirement.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Get a daily dose of Vietnam Tribune news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Vietnam Tribune.
More InformationURUMQI, July 12 (Xinhua) -- In Shihezi, a major cotton producing area in northwest China's Xinjiang Uygur Autonomous Region, Esquel...
Phnom Penh [Cambodia], July 12 (ANI): Union Minister of State for External Affairs Pabitra Margherita reaffirmed the 'strong and enduring...
The arbitration has in fact become an anchor around the Filipino people's neck, weighing the nation down economically, said Herman...
Kathmandu [Nepal], July 12 (ANI): The Trekking Agencies Association of Nepal (TAAN), an umbrella organisation of mountain tourism entrepreneurs,...
New Delhi [India], July 12 (ANI): The Ministry of External Affairs (MEA) has underlined India's increasing involvement in the Indo-Pacific...
Dhaka [Bangladesh], July 12 (ANI): The three-day second-round tariff talks between Bangladesh and the United States have ended without...
ATLANTA, Georgia: The United States is facing its worst measles outbreak in more than three decades, with 1,288 confirmed cases so...
In the past month alone, 23 Israeli soldiers have been killed in Gaza—three more than the number of remaining living hostages held...
LONDON, U.K.: At least 13 people are believed to have taken their own lives as a result of the U.K.'s Post Office scandal, in which...
WASHINGTON, D.C.: Travelers at U.S. airports will no longer need to remove their shoes during security screenings, Department of Homeland...
WASHINGTON, D.C.: An elaborate impersonation scheme involving artificial intelligence targeted senior U.S. and foreign officials in...
SLUBICE, Poland: Poland reinstated border controls with Germany and Lithuania on July 7, following Germany's earlier reintroduction...